￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Crizotinib is highly effective against ROS1 rearrangement in advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Crizotinib is a targeted drug for the treatment of patients with ROS1-positive advanced lung cancer

2025-10-19 11:44:20

Check Details
First-line treatment for ALK-positive lung cancer-crizotinib

2025-10-19 11:44:20

Check Details
Research progress of Lorlatinib in ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
The third generation ALK/ROS1 mutated lung cancer targeting drug: lorlatinib

2025-10-19 11:44:20

Check Details
Analysis of efficacy and adverse reactions of lorlatinib in the first-line treatment of ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
Has the ALK inhibitor lorlatinib been approved for marketing in China? How to buy?

2025-10-19 11:44:20

Check Details
Lorlatinib is expected to improve the treatment of ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
Therapeutic efficacy data of the third-generation drug lorlatinib for lung cancer

2025-10-19 11:44:20

Check Details
Can Lorlatinib be used as first-line therapy for ALK+ NSCLC?

2025-10-19 11:44:20

Check Details
Effect data of patients with ALK/ROS1 rearranged NSCLC treated with Lorlatinib

2025-10-19 11:44:20

Check Details
The new generation ALK/ROS1 inhibitor Lorlatinib was granted breakthrough drug designation by the FDA

2025-10-19 11:44:20

Check Details
Category
相关知识